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 Phenotype consensus is required to enable large-scale genetic 
consortium studies of food allergy 
 To the Editor, 
 Recent genome-wide association studies (GWAS) have identified 
multiple candidate variants for food allergy (FA). 1-3 In February 2019, 
we convened to develop an International FA Consortium (InFAC) for 
genetic research (Vancouver, Canada). The main goal of InFAC was 
to enable large-scale international collaborations on FA genetics, 
since polygenic diseases require large samples to identify associ-
ated genetic variants. One of the barriers addressed was the need 
for consensus phenotype definitions, as direct comparisons of previ-
ous findings are complicated by heterogeneity in the FA definitions 
applied. In particular, asymptomatic sensitized individuals and self-
reported FA without laboratory testing pose significant challenges. 
Another key issue is the definition of appropriate controls which 
range from biobanked general population controls to non-atopic 
controls with negative sensitization testing or absence of clinical 
history. 
 The double-blind, placebo-controlled food challenge (DBPCFC) 
is the gold standard for FA diagnosis, but some large-scale genetic 
resources may not have these data and it may be difficult to find an 
adequate number of individuals meeting this stringent FA definition. 
Some investigators have performed placebo-controlled food chal-
lenges without double-blinding or utilized open oral food challenges 
(OFC), both of which still provide strong clinical support for a diag-
nosis of FA. Use of standard cutoffs for in vivo and in vitro diagnos-
tic tests as a surrogate for DBPCFC is not well established, because 
positive predictive value (PPV) cutoffs vary greatly across popula-
tions. We perceive the definition of FA phenotype is a major barrier 
toward making progress in FA genetic research. A key outcome from 
this meeting was to develop consensus around FA inclusion criteria 
for large-scale genetic research. 
 Two key consensus statements emerged regarding large-scale 
genetic FA research and are presented in Table  1a . 
 What determines a convincing history of an IgE-mediated allergic 
reaction to a specific food is controversial. In practice, allergists use 
experienced clinical judgment regarding history, symptoms, and 
testing to make a diagnosis of FA. Several definitions and scores de-
scribing an allergic response were considered, including the World 
Allergy Organization definition of anaphylaxis (online supplement) 4 
and the Astier score for reaction severity 5 (Table  S2 ), but neither 
included all criteria deemed to be essential for a convincing history 
of FA. We therefore agreed that for the purposes of phenotyping for 
genetic studies, a convincing history should involve the following: 
a) exposure by ingestion of the food allergen b) onset of symptoms 
within 2 hours of exposure with resolution within 24 hours, and c) 
only objective symptoms (Table  1b ). Two-organ system involvement 
is not required and treatment is not considered. Local symptoms 
through contact of the food allergen with the skin or oral mucosa 
are not sufficient. Reactions solely identified by subjective symp-
toms (Table  1b ) or linked to unclear exposure (ie, after consuming 
multiple food allergens and cross-contamination) (Table  1b ) are not 
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considered convincing. Some subjective symptoms were identified 
by allergists in the group as having weight in a clinical history of FA, 
but most felt that these symptoms and anaphylaxis would be accom-
panied by objective symptoms. 
 Tier 4 of statement 2 is the most controversial as the challenge is 
to define “minimal criteria” for FA. Many large-scale genetic studies 
lack a detailed clinical history but have laboratory testing, allowing 
the allergic individuals in these studies to be captured by Tier 4. 
While we realize that this may lead to the inclusion of some indi-
viduals with asymptomatic sensitization, there was consensus that 
Tier 4, using the currently accepted 95% PPV cutoffs for SPT or sIgE 
(Table  1c , Table  S1 online supplement), will generate a reasonable 
 TA B L E   1C     Proposed 95% PPV cutoffs for skin prick test (SPT) 
and specific IgE (sIgE) 
 Food type and age  SPT size (mm) 
 sIgE levels 
(kU A /mL) 
 Peanut  ≥8  ≥14 
 Peanut in ≤2 years  ≥8  ≥14 
 Cow ' s milk  ≥8  ≥15 
 Cow ' s milk in ≤2 years  ≥8  ≥5 
 Hen ' s egg white  ≥8  ≥7 
 Hen ' s egg white in ≤2 years  ≥8  ≥2 
 Adapted from Nowak-Wegrzyn et al 2017, 9 see online supplement 
(Table  S1 ) 
 1  Initial collaborations should concentrate on peanut, hen ' s egg, and cow ' s milk allergy due 
to difficulties with other types of FA in regard to low prevalence and lack of consensus 
regarding diagnostic criteria (ie, 95% PPV cutoffs for allergen-specific IgE (sIgE) and skin 
prick test (SPT)) outside of DBPCFC 
 Statement 1 is made with the assumption that the underlying genetic model involves specific 
risk loci for specific foods. If one assumes that all FA are influenced by the same genetic risk 
loci, a study design grouping all FA may be more powerful, but would require DBPCFC for 
all cases that do not have well-established diagnostic criteria outside of DBPCFC. 
 2  Consider 4 tiers of FA diagnostic criteria, from most stringent to more moderate. These 
include the following, in order of decreasing stringency (Figure  1A ): 
 Tier 1: Convincing reaction confirmed by oral food challenge 
 Tier 2: Convincing clinical history of a reaction with objective symptoms and confirmed 
exposure (Table  1b and below) with evidence of sensitization at or above 95% PPV 
cutoffs for SPT  OR sIgE (Table  1c , Table  S1 , online supplement) 
 Tier 3: Convincing clinical history of a reaction with objective symptoms and confirmed 
exposure (Table  1b ), with any sensitization ≥ 3mm SPT OR sIgE ≥ 0.35kU A /L 
 Tier 4: No convincing history with sensitization at or above 95% PPV cutoffs for 
SPT or sIgE 
 TA B L E   1 A     InFAC 2019 statements 
regarding food allergy phenotypes for 
genetic research collaborations 
 TA B L E   1 B     Objective versus subjective symptoms occurring within 2 h of ingestion of allergen 
 System  Objective Symptoms  Subjective Symptoms 
 Airway  Angioedema of eyes, lips, tongue, oral cavity, and pharynx  Isolated pruritus (skin, eyes, lips, tongue, 
throat, and nose) with no visible symptoms 
 Dysphonia, hoarseness, and laryngeal edema  Throat congestion 
 Shortness of breath  
 Wheezing  Chest tightness/pain 
 Coughing  
 Sneezing episodes  
 Rhinorrhea  Nasal congestion 
 Cutaneous  Conjunctivitis, tearing  Isolated perioral redness 
 Erythema/flushing  Skin discomfort 
 Urticaria  Contact urticaria from food allergen contact, 
without ingestion 
 Neurologic  Loss of consciousness/fainting  Dizziness, light-headedness 
 Seizures  Feeling of impending doom 
 Cardiac  Tachycardia  
 Hypotension  
 Gastrointestinal  Emesis/Diarrhea  Abdominal pain 
  Nausea 
 Genitourinary   Uterine cramping/contractions 
 Adapted from Pajno et al 2017, Allergy. 8 
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level of certainty to allow international collaboration at the most in-
clusive level. However, there is a trade-off as categories become less 
stringent—available samples will increase, but at the cost of potential 
misclassification. 
 The mode of inheritance, penetrance of risk genes, and their fre-
quency in the study population determine sample size require-
ments. For GWAS, sample size requirements depend greatly upon 
the research question being asked, the effect size, and the com-
parator group. Risk variants with large effect sizes do not require 
as large of a sample size, but many polygenic diseases do not have 
risk variants with large effect sizes. The genetic model assumed in 
the experiment is key and could include the following: a) genetic risk 
variants exist for development of FA to a specific food, b) genetic 
risk variants exist that are common to developing all food allergies, 
but the specific allergy is determined by non-genetic factors c) ge-
netic risk variants exist that are common to the development of all 
atopic diseases (atopic dermatitis, allergic asthma, allergic rhinitis, 
and eosinophilic esophagitis) but which one develops is determined 
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by interaction effects either genetic (gene-gene) or non-genetic 
(gene-environment) factors, and d) a combination of all of these 
assumptions. 
 Control group phenotypes also play a key role in sample size re-
quirements: hypercontrols—individuals who have no history of FA, 
or atopic diseases, and laboratory testing that indicates that they are 
not sensitized to foods—are helpful to increase power to detect ge-
netic variants. However, it would be difficult to separate genetic risk 
factors for atopic tendency from those that cause FA, and there may 
be an age discrepancy and generational differences between cases. 
Population-based controls may also be used, with consideration of 
potential misclassification; prevalence of the FA being studied may 
be low in the population, but the combined effect of multiple atopic 
conditions, some of which may be self-resolving, may not be negligi-
ble. Use of controls with atopic diseases for investigation of FA may 
be difficult given the waxing and waning conditions of the atopic 
march. 
 Case and control recruitment can be costly (both monetarily 
and in time) due to the diagnostic history, testing, and follow-up re-
quired to achieve well-defined allergic phenotypes. Smaller sample 
sizes may have the power to detect genetic variants of interest in 
circumstances where the genetic risk factor has a large effect size 
and there are well-phenotyped cases and hypercontrols, but sample 
size requirements will vary depending upon the genetic model, the 
population studied, and the question asked. 
 For genetic studies, samples can be taken from a variety of tis-
sue types. However, for epigenetic studies, sample type is key as 
each tissue will exhibit a specific epigenetic signature. Some sample 
types, for example blood samples, may be more difficult to use in 
epigenetic studies due to the variety of cell populations within the 
sample. For FA, which presents with a diverse variety of effects in 
various systems and thus has no single tissue affected, most studies 
have focused on blood samples. For epigenetic studies, the sample 
size is dependent on the purity of the tissue and how enriched that 
tissue is for the disease-associated signal, in addition to the variables 
mentioned previously for GWA studies. 
 Recent publications on FA genetics have identified many potential 
loci for atopic diseases. However, the underlying genetic model for 
these diseases is unknown. Atopic conditions may share common 
genetic susceptibility, and environmental factors may determine 
which specific atopic disease develops; alternatively, each atopic 
disease may have its own risk variants, with transient and persistent 
forms differing in genetic susceptibility (Figure  1B ). 
 These complex questions cannot be answered by studies with 
small samples, and genetic and molecular studies are inherently 
costly endeavors. Pooling data across studies is a cost-effective 
method to increase power. This will require a harmonization of 
phenotyping to ensure that efforts are not diluted by varying phe-
notypes. A balance between the gold standard and well-accepted 
global clinical and laboratory surrogate markers is required, as well 
as data on the transferability of IgE values from different plat-
forms. While the gold standard of phenotyping of FA is DBPCFC, 
for research purposes we propose various levels of phenotyping to 
maximize potential collaborations. Findings can be subsequently 
verified in FA diagnosed by the gold standard. 
 Some may question the utility of genetic markers for FA due to 
ample evidence on the role of the environment in the development 
of allergies. 6 In an era of precision medicine, biologics, oral, epicuta-
neous, and sublingual immunotherapy, genetic markers may signifi-
cantly enhance decision-making. 7 Genetic susceptibility may have a 
role in the development of natural or treatment-induced tolerance. 
 Understanding the genetic architecture of FA remains a research 
imperative as accurate polygenic models may inform differing natu-
ral histories (ie, resolution versus persistence of FA), biomarker dis-
covery, and identifies patients most likely to benefit from targeted 
primary prevention and immunotherapy. This aligns with efforts to 
provide more specific recommendations among patient subgroups, 
as considerable heterogeneity exists even among similar FA pheno-
types. Thus, it is of utmost importance to pursue joint global ap-
proaches to identify the genetic drivers of FA. To succeed, these 
efforts need to be based on a consensus of how to diagnose FA. 
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